Coherus BioSciences Inc CHRS:NASDAQ

Last Price$20.20NASDAQ Previous Close - Last Trade as of 4:15PM ET 9/13/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$14.00 (3)
Ask (Size)$20.22 (38)
Day Low / HighN/A - N/A
Volume530.4 K
 

View Biotechnology IndustryPeer Comparison as of 09/13/2019

 

Coherus BioSciences Inc ( NASDAQ )

Price: $20.20
Change: +0.26 (1.30%)
Volume: 530.4 K
4:15PM ET 9/13/2019
 
 

Eidos Therapeutics Inc ( NASDAQ )

Price: $45.00
Change: -0.53 (1.16%)
Volume: 223.7 K
4:00PM ET 9/13/2019
 
 

Heron Therapeutics Inc ( NASDAQ )

Price: $20.51
Change: 0.00 (0.00%)
Volume: 1.1 M
4:00PM ET 9/13/2019
 
 

Insmed Inc ( NASDAQ )

Price: $18.82
Change: -0.19 (1.00%)
Volume: 685.8 K
4:00PM ET 9/13/2019
 
 

Audentes Therapeutics Inc ( NASDAQ )

Price: $31.74
Change: -0.09 (0.28%)
Volume: 5.2 K
4:00PM ET 9/13/2019
 

Read more news Recent News

Coherus BioSciences' Q3, 2019, 2020 Full Year Earnings Estimates Raised
2:56AM ET 9/10/2019 MT Newswires

Consensus estimates for Coherus BioSciences Inc's (NASDAQ:CHRS, Recent Price: 19.70) Q3 ending September 30, 2019, and the full year forecasts for 2019 and...

2019, 2020, and Q3 Earnings Estimates for Coherus BioSciences Reduced
3:31AM ET 9/04/2019 MT Newswires

Coherus BioSciences Inc's (NASDAQ:CHRS, Recent Price: 21.92) consensus estimates for Q3 ending September 30, 2019, and the forecasts for 2019 and 2020 have...

Coherus BioSciences' Q3 and Full Year Earnings Estimates Projected Higher
11:51PM ET 8/14/2019 MT Newswires

The September 30, 2019 quarterly, and December 31, 2019 full year earnings estimates for Coherus BioSciences Inc (NASDAQ:CHRS, Recent Price: 18.59) have...

Coherus BioSciences' 2020 Earnings Projection Targeted Higher
11:46PM ET 8/13/2019 MT Newswires

Coherus BioSciences Inc's (NASDAQ:CHRS, Recent Price: 19.37) 2020 forecasted earnings estimate for the year ending December 31, 2020 has been increased....

View all Commentary and Analysis

The Play On Coherus BioSciences
1:52AM ET 9/13/2019 Seeking Alpha

Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q2 2019 Results - Earnings Call Transcript
8:51PM ET 8/01/2019 Seeking Alpha

Biotechs' Second-Half Battle
12:32PM ET 7/22/2019 Seeking Alpha

Daily Insider Ratings Round Up 7/2/19
2:36PM ET 7/04/2019 Seeking Alpha

Company Profile

Business DescriptionCoherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA. View company web site for more details
Address333 Twin Dolphin Drive
Redwood City, California 94065
Phone+1.650.649.3530
Number of Employees232
Recent SEC Filing08/23/20194
Chairman, President & Chief Executive OfficerDenny M. Lanfear
Chief Operating OfficerVincent R. Anicetti
Chief Financial OfficerJean-Frédéric Viret
Chief Technical OfficerPeter K. Watler

Company Highlights

Price Open$20.02
Previous Close$20.20
52 Week Range$8.32 - 23.43
Market Capitalization$1.4 B
Shares Outstanding69.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/14/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.71
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-97.77%
Return on Equity686.15%

Analyst Ratings as of 08/09/2019

Buy
7
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset